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Abstract: Increasing evidence suggests that μ opioid receptor (MOP) expression is altered during the development of and 
withdrawal from substance dependence. Although anti-MOP antibodies have been hypothesized to be useful for   
estimating MOP expression levels, inconsistent MOP molecular weights (MWs) have been reported in studies using   
anti-MOP antibodies. In the present study, we generated a new anti-MOP antibody (N38) against the 1-38 amino acid  
sequence of the mouse MOP N-terminus and conducted Western blot analysis with wildtype and MOP knockout   
brain lysates to determine the MWs of intrinsic MOP. The N38 antibody detected migrating bands with relative MWs of 
60-67 kDa in the plasma membrane fraction isolated from wildtype brain, but not from the MOP knockout brain. These 
migrating bands exhibited semi-linear density in the range of 3-30 μg membrane proteins/lane. The N38 antibody may be 
useful for quantitatively detecting MOP. 
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INTRODUCTION 
 The  μ opioid receptor (MOP) belongs to the superfamily 
of seven-transmembrane-spanning G protein-coupled recep-
tors. Many pharmacological data using gene knockout mice 
have shown that MOP is a preferred target of opioid drugs, 
such as morphine and fentanyl, and that MOP appears   
to play a critical role in mediating major clinical effects   
of opioids, including analgesia, dependence, tolerance, and 
respiratory depression [1]. 
  MOP expression has been reportedly altered in substance 
abuse [2]. MOP protein expression decreases after ethanol 
treatment in various brain regions [3]. MOP binding poten-
tial also decreases in the cortex and increases in the striatum, 
and altered expression is associated with alcohol craving in 
alcohol-dependent subjects undergoing alcohol withdrawal 
[4, 5]. Furthermore, during chronic cocaine treatment and 
withdrawal from chronic cocaine administration, MOP 
mRNA levels increase in the nucleus accumbens [6, 7]. 
However, in other brain regions such as limbic regions, 
chronic cocaine treatment downregulates MOP mRNA ex-
pression [8]. 
  MOP has been detected by numerous methods, including 
Northern blot analysis, RNase protection assay, real-time 
reverse transcription polymerase chain reaction (RT-PCR),   
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immunohistochemistry, and Western blot analysis. Among 
these detection methods, Western blot analysis with MOP-
specific antibodies is effective for quantitatively measuring 
MOP protein expression. Although a number of anti-MOP 
antibodies have been generated, these anti-MOP antibodies 
produce immunoreactive bands with a diverse range of mo-
lecular weights (MWs). MOP MWs are different between 
glycosylated and non-glycosylated types [9, 10]. Addition-
ally, MOP forms dimers whose MWs are different from 
monomers [9]. MOP MWs also differ as a result of various 
isolating conditions, such as pH and the presence or absence 
of reducing agents [11]. 
  In the present study, we generated a new anti-MOP anti-
body against the 1-38 amino acid sequence of the mouse 
MOP amino-terminus (N-terminus) and tested it with other 
anti-MOP antibodies generated against different MOP re-
gions using brain lysates from MOP knockout mice. Fur-
thermore, we investigated the linearity of MOP detection 
using the N38 antibody in the physiological range of protein 
concentrations. 
MATERIALS AND METHODS 
Animals 
  C57BL/6J mice were purchased from CLEA Japan Inc. 
(Tokyo, Japan). MOP knockout mice were generated as pre-
viously described [12]. The targeted allele of the MOP gene 
lacks exon 1, which encodes the coding region correspond-
ing to 95 amino acids of the MOP N-terminus starting with 
methionine. After backcrossing to C57BL/6J for 10 genera-
tions, MOP knockout mice were maintained to cross between 220    Current Neuropharmacology, 2011, Vol. 9, No. 1  Kasai et al. 
heterozygotes to produce all genotype littermates. MOP 
knockout mouse genotyping was performed by PCR using 
GoTaq DNA polymerase (Promega, Madison, WI, USA) 
with a common forward primer and two reverse primers at 
the neo-resistant gene only in the knockout allele and at the 
5’ flanking region of the MOP gene only in the wildtype 
allele. The mice were housed five per cage in an environ-
ment maintained at 22 ± 2°C with 55 ± 5% relative humidity 
and a 12 h light/12 h dark cycle (lights on 8:00 a.m. to 8:00 
p.m.). The mice had ad libitum access to a standard labora-
tory diet and water. The experimental procedures were ap-
proved by the Institutional Animal Care and Use Committee 
of the Tokyo Institute of Psychiatry. 
Antibody Production 
  The nucleotide sequences encoding the N-terminus of 
mouse MOP (amino acid residues 1-38, Accession No. 
U19380) were amplified by PCR using a single-strand 
cDNA library prepared from the adult mouse brain and sub-
cloned into the BamHI/EcoRI site of the pGEX4T-2 plasmid 
vector (Amersham Biosciences, Bucks, UK) to be expressed 
as the glutathione S-transferase (GST) fusion protein. The 
fusion protein was emulsified with Freund’s complete adju-
vant in the first immunization and incomplete adjuvant in the 
subsequent immunization (DIFCO, Detroit, MI, USA) and 
injected subcutaneously into female rabbit at intervals of 2 
weeks. Two weeks after the sixth injection, the MOP-
specific antibody (N38) against the 1-38 amino acid se-
quences of the N-terminus of mouse MOP was collected by 
affinity purification using GST-free polypeptides coupled to 
CNBr-activated Sepharose 4B (Amersham Biosciences). 
GST-free peptides were prepared by in-column thrombin 
digestion of GST fusion proteins bound to glutathione-
Sepharose 4B media. 
Membrane Preparation from Brain 
  The cortex from adult male mouse brain was collected 
and homogenized in ice-cold 0.32 M sucrose solution con-
taining 1 mM ethylene glycol tetraacetic acid (EGTA) and 
protease inhibitors (Roche, Basel, Switzerland). The total 
homogenate (T) was subjected to centrifugation at 800  g 
for 12 min at 4ºC to remove the nuclei (P1), and the super-
natant was further centrifuged at high speed at 22,000  g for 
20 min at 4ºC. The supernatant (S2) was removed, and the 
pellet (P2) was resuspended in 0.32 M sucrose solution con-
taining 1 mM EGTA and protease inhibitor and used as the 
membrane fraction for Western blot analyses. Protein con-
tent was determined by the Bradford method using a Bio-
Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, 
USA) according to the manufacturer’s instructions. 
Western Blot Analyses 
  The anti-MOP antibodies 44-308G and AB5511 against 
chemically synthetic peptides from the internal region and 
carboxy-terminus (C-terminus), respectively, of MOP were 
purchased from Biosource International Inc. (Camarillo, CA, 
USA) and Chemicon International Inc. (Hampshire, UK), 
respectively. Protein samples were diluted in Laemmli’s 
sample buffer, and 0.3-30 g of total protein/lane was   
subjected to sodium dodecyl sulfate-polyacrylamide gel   
electrophoresis (SDS-PAGE) using 5-20% gradient SDS-
polyacrylamide gels (ATTO, Tokyo, Japan). The resolved 
proteins were transferred onto polyvinylidene difluoride 
(PVDF) membranes (Nippon Genetics Co. Ltd., Tokyo, Ja-
pan) using a Trans-Blot SD transfer cell (Bio-Rad). Follow-
ing transfer, membranes were washed with Tris-buffered 
saline containing 0.05% Tween-20 (TBST) and then blocked 
in Blocking One (Nacalai Tesque Inc., Kyoto, Japan) for 1 h 
at room temperature. The membranes were then incubated 
for 5 days with N38 (1:100-1:400) or for 1 day with 44-
308G (1:5,000) or AB5511 (1:5,000-1:20,000) rabbit poly-
clonal antibodies in TBST containing 10% Blocking One at 
4ºC. After washing three times for 10 min in TBST, mem-
branes were incubated with peroxidase-labeled secondary 
antibody (1:50,000; Zymed Laboratories Inc., South San 
Francisco, CA, USA) for 1 h at room temperature. The 
membranes were washed in TBST, incubated with Super-
Signal WestDura Extended Duration Substrate (Pierce Bio-
technology Inc., Rockford, IL, USA) for 10 min, and ex-
posed to electrogenerated chemiluminescence (ECL) films 
(Amersham Biosciences). ECL films were scanned densi-
tometrically, and the optical density of bands was quantified 
using Image J version 1.38 software (http://rsb.info.nih.gov/ij/; 
accessed October 9, 2009). 
RESULTS 
  Anti-MOP antibodies have been produced since the early 
1990s and have yielded inconsistent results with regard to 
the MW of the MOP protein. We generated a new antibody 
against the 38 amino acid sequence of the mouse MOP   
N-terminus (MDSSAGPGNISDCSDPLAPASCSPAPGS-
WLNLSHVDGN) and determined the antibodies’ immu-
nological specificities for MOP by Western blot analyses. 
  First, the N38 anti-MOP antibody was compared with the 
other antibodies (44-308G and AB5511) which were commer-
cially available. The 44-308G and AB5511 antibodies were 
generated against the internal region of human MOP and the 
C-terminus of rat MOP, respectively. Plasma membrane pro-
teins (P2 fraction) derived from the cortex of adult male 
C57BL/6J mice were resolved by SDS-PAGE, transferred 
onto PVDF membrane, and stained with three anti-MOP 
antibodies. Numerous bands around 30-110 kDa were 
stained in the total homogenate (T) with all three antibodies 
(Fig. (1)). Approximately 40, 44, 60-67, and 95 kDa proteins 
were stained with the N38 antibody for 5 days (indicated by 
arrowheads in Fig. (1) left panel). However, no immunoreac-
tive bands were detected with the N38 antibody for 1 day 
(data not shown). 30, 47-55, 55, 60, and 95 kDa proteins 
were detected with the 44-308G antibody, and 33-38, 40-45, 
50, and 60-67 kDa proteins were detected with the AB5511 
antibody for 1 day (indicated by arrowheads in center and 
right panels in Fig. (1)). In these immunoreactive bands, only 
the migrating bands with relative MWs of 60-67 kDa stained 
by either N38 or AB5511 antibodies were accumulated in the 
P2 fraction (indicated by arrows in Fig. (1)). 
  For identification of MOP in a number of bands detected 
by three anti-MOP antibodies, Western blot analyses were 
performed with the P2 fraction prepared from the cortex of 
MOP knockout mice previously generated by Sora et al. 
(1997) [12]. These MOP knockout mice lacked exon 1, in-
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virtually no MOP immunoreactivity in the spinal cord dorsal 
horn [12]. The 60-67 kDa migrating bands were completely 
abolished in the knockout P2 fraction stained with N38 or 
AB5511 antibodies (indicated by arrows in left and right 
panels in Fig. (2)). The intensity of two weak bands around 
40-45 kDa was attenuated in the knockout P2 fraction (indi-
cated by arrowhead in Fig. (2)). The other bands that did not 
accumulate in the C57BL/6J P2 fraction were detected in the 
knockout P2 fraction with three anti-MOP antibodies. These 
results indicate that the N38 and AB5511 antibodies detected 
intrinsic MOP proteins as 60-67 kDa migrating bands in the 
P2 fraction from adult brain. 
  We additionally conducted Western blot analyses with 
high antibody concentrations to detect quantitatively smaller 
amounts of MOP, such as physiological levels of MOP pro-
tein expression. The N38 and AB5511 antibodies were used 
at a dilution of 1:100 and 1:5,000, respectively. The migrat-
ing bands of MOP proteins were detected at concentrations 
of 1-30 μg and 3-30 μg total protein/lane by N38 and 
AB5511 antibodies in the P2 fraction from adult male 
C57BL/6J brain, respectively (indicated by arrows in   
Fig. (3A)). The density of migrating MOP protein bands 
exhibited semi-linearity at 3-30 μg total protein/lane in 
Western blot analyses with either N38 or AB5511 antibodies 
(Fig. (3B)). More intense MOP bands were detected by   
N38 than by AB5511 antibodies, suggesting that the N38 
antibody is more suitable than AB5511 for quantitative assay 
of MOP protein levels by Western blot analysis. 
DISCUSSION 
  The N38 anti-MOP antibody increased 60-67 kDa mi-
grating bands in the wildtype P2 fraction but not in the 
MOP-knockout P2 fraction. In a similar range of MWs, the 
same patterns of migrating bands were detected as MOP only 
by Arvidsson et al. (1995) [13] and Chalecka-Franaszek et al. 
(2000) [14]. Similar to other G protein-coupled receptors, 
MOP contains sites for N-linked glycosylation (Asn-X-
Cys/Ser/Thr) in the extracellular N-termini in the mouse, rat, 
and human MOP (four positions in mouse MOP and five 
positions in rat and human MOP). The MWs of MOP treated 
with various glycosidases were markedly reduced to a range 
of 40-50 kDa [9, 10], suggesting that glycosyl residues 
greatly contributed to MOP MWs. The variations of glycosy-
lation, such as the type and number of glycosylated residues, 
may result in migrating bands of MOP. The two weak bands 
around 40-45 kDa in the wildtype P2 fraction were virtually 
eliminated in the MOP knockout P2 fraction by staining with 
 
 
 
 
 
Fig. (1). Western blot analyses with three anti-MOP antibodies 
produced against peptides from different MOP regions. Anti-MOP 
rabbit polyclonal antibodies (N38, 44-308G, and AB5511) were 
produced against the N-terminus, internal region, and C-terminus of 
MOP, respectively. Total cortex homogenate (T) from adult male 
C57BL/6J mice was fractionated to nuclear fraction (P1), cytoplas-
mic membrane fraction (P2), and cytoplasm fraction (S2) by two-
step centrifugation at 800  g and subsequently 22,000  g. 10 μg 
of each fraction was subjected to SDS-PAGE. Protein blots were 
incubated with anti-MOP antibodies at appropriate dilution (N38, 
1:400; 44-308G, 1:5,000; AB5511, 1:20,000), followed by reaction 
with secondary antibody and visualization. 
 
 
 
 
 
Fig. (2). Western blot analyses at the P2 fraction derived from wild-
type and Oprm1 knockout mice. The P2 fractions were isolated 
from the cortex of wildtype (WT) and Oprm1 knockout (KO) adult 
male mice. 10 μg of the P2 fraction from each genotype was sub-
jected to SDS-PAGE. Protein blots were reacted with anti-MOP 
antibodies at appropriate dilution (N38, 1:400; 44-308G, 1:5,000; 
AB5511, 1:20,000), followed by reaction with secondary antibody 
and visualization. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Western blot analyses with N38 and AB5511 antibodies 
for MOP detection in a protein dose-dependent manner. The P2 
fractions were isolated from the cortex of adult male C57BL/6J 
mice. 0.3, 1, 3, 10, and 30 μg of proteins were subjected to SDS-
PAGE. Protein blots were reacted with N38 (1:100) and AB5511 
(1:5,000) antibodies, followed by reaction with secondary antibody 
and visualization (A). The optical density of migrating bands indi-
cated by arrows around 60-67 kDa was quantified using Image J 
software (B). 222    Current Neuropharmacology, 2011, Vol. 9, No. 1  Kasai et al. 
AB5511 antibody (right panel in Fig. (2)). Unknown is 
whether non-glycosylated MOP exists in physiological con-
ditions or derives from deglycosylation during isolation of 
the P2 samples, but these two weak bands may correspond to 
non-glycosylated MOP. 
  The N38 anti-MOP antibody is against the 1-38 amino 
acid sequence of mouse MOP that exists in the extracellular 
N-terminus domain of MOP. The N-terminus of the MOP 
protein is more diversified than other regions in mouse, rat, 
and human (21 amino acid differences in the first 100 amino 
acids of the N-terminus, two differences in the next 200 
amino acids, and five differences in the last 100 amino ac-
ids). Additionally, both N- and C-termini of mouse opioid 
receptors show a greater variety of amino acid sequences 
than the internal region among the three types of mouse 
opioid receptors. The relatively unconserved sequence of the 
MOP N-terminus may cause the high reactivity and specific-
ity of the N38 anti-MOP antibody. Although a control ex-
periment should be conducted with MOP-absorbed N38 an-
tibody because of remaining nonspecific immunoreactivity, 
this antibody may be useful for studies detecting MOP pro-
teins in mouse tissues. 
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